All News about Kalvista Pharmaceuticals Inc
![](https://mms.businesswire.com/media/20240802335240/en/670569/5/Kalvista-Logo-Final-01.jpg)
![](https://cdn.benzinga.com/files/images/story/2024/07/12/xrdDAFsc26aiRI2-j5041054601835708275-t23.jpeg?width=1200&height=800&fit=crop)
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
![](https://mms.businesswire.com/media/20240711453276/en/670569/5/Kalvista-Logo-Final-01.jpg)
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_4.png?width=1200&height=800&fit=crop)
Recap: KalVista Pharma Q3 Earnings
March 11, 2024
Via Benzinga
![](https://mms.businesswire.com/media/20240702602098/en/670569/5/Kalvista-Logo-Final-01.jpg)
![](https://mms.businesswire.com/media/20240627071012/en/670569/5/Kalvista-Logo-Final-01.jpg)
![](https://mms.businesswire.com/media/20240618507569/en/670569/5/Kalvista-Logo-Final-01.jpg)
![](https://mms.businesswire.com/media/20240606656084/en/670569/5/Kalvista-Logo-Final-01.jpg)
![](https://mms.businesswire.com/media/20240604383516/en/670569/5/Kalvista-Logo-Final-01.jpg)
![](https://mms.businesswire.com/media/20240603431601/en/670569/5/Kalvista-Logo-Final-01.jpg)
![](https://mms.businesswire.com/media/20240531104408/en/670569/5/Kalvista-Logo-Final-01.jpg)
![](https://mms.businesswire.com/media/20240524679559/en/670569/5/Kalvista-Logo-Final-01.jpg)
![](https://mms.businesswire.com/media/20240521674499/en/670569/5/Kalvista-Logo-Final-01.jpg)
![](https://mms.businesswire.com/media/20240502658624/en/670569/5/Kalvista-Logo-Final-01.jpg)
![](https://mms.businesswire.com/media/20240501899140/en/670569/5/Kalvista-Logo-Final-01.jpg)
![](https://mms.businesswire.com/media/20240422400971/en/670569/5/Kalvista-Logo-Final-01.jpg)
![](https://mms.businesswire.com/media/20240403658389/en/670569/5/Kalvista-Logo-Final-01.jpg)
![](https://mms.businesswire.com/media/20240402778985/en/670569/5/Kalvista-Logo-Final-01.jpg)
![](https://mms.businesswire.com/media/20240318610099/en/670569/5/Kalvista-Logo-Final-01.jpg)
![](https://mms.businesswire.com/media/20240312355965/en/670569/5/Kalvista-Logo-Final-01.jpg)
![](https://mms.businesswire.com/media/20240311841357/en/670569/5/Kalvista-Logo-Final-01.jpg)
![](https://mms.businesswire.com/media/20240308093167/en/670569/5/Kalvista-Logo-Final-01.jpg)
![](https://mms.businesswire.com/media/20240307682920/en/670569/5/Kalvista-Logo-Final-01.jpg)
![](https://mms.businesswire.com/media/20240306952725/en/670569/5/Kalvista-Logo-Final-01.jpg)
![](https://mms.businesswire.com/media/20240304835396/en/670569/5/Kalvista-Logo-Final-01.jpg)
![](https://mms.businesswire.com/media/20240227931159/en/670569/5/Kalvista-Logo-Final-01.jpg)
![](https://mms.businesswire.com/media/20240226691447/en/670569/5/Kalvista-Logo-Final-01.jpg)
![](https://mms.businesswire.com/media/20240220763544/en/670569/5/Kalvista-Logo-Final-01.jpg)
KalVista Pharmaceuticals Awarded UK Innovation Passport for Sebetralstat
February 20, 2024
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.